Observation shows baseline mutation detection in cell-free DNA predicts poor outcomes in adults with LCH, indicating potential for improved management strategies.
Key Points
Positive mutation detection in cell-free DNA correlates with worse treatment outcomes in patients with Langerhans cell histiocytosis.
Patients with positive cell-free DNA had a significantly lower overall response rate to treatment, 74.5% compared to 96.8%.
Assessment of inflammatory cytokines revealed significant elevation in patients with positive cell-free DNA, indicating a hyperinflammatory state.
Early negativity in cell-free DNA post-therapy was associated with better prognosis and a more favorable event-free survival rate.